Market Cap: $736.02M
GC
Geron Corporation
GERN
NASDAQ (NASDAQ Global Select)USD
Market Cap: $736.02M
Avaí Bio Sets New Standards in Anti-Aging Therapy Production Avaí Bio, Inc., a prominent figure in the biotechnology sector, is making important strides in the anti-aging therapy market, which is pois…
Avaí Bio Positions Itself at the Forefront of the Anti-Aging Therapy Market Avaí Bio, Inc., a biotechnology company that specializes in cell-based therapies targeting diabetes and age-related disorder…
Avaí Bio's Strategic Initiative in Anti-Aging Therapies Avaí Bio, Inc. stands at the vanguard of the burgeoning global anti-aging therapy market, a sector expected to surpass $420 billion by 2030. Thi…
Geron Corporation Reports Key Insights from Fourth Quarter Earnings Call Geron Corporation, a biopharmaceutical company focused on innovative oncology treatments, presents significant developments in…
Geron Corporation Unveils Q4 Earnings Results, Emphasizing Strategic Oncology Developments Geron Corporation has recently announced its fourth-quarter earnings results, offering a comprehensive overvi…
Geron Corporation Highlights Its Innovative Approach to Oncology in Recent Earnings Announcement Geron Corporation emphasizes its commitment to pioneering treatments in oncology as it announces its fo…
GT Biopharma Advances Immunotherapy for Blood Cancers with GTB-3650 GT Biopharma, Inc. is making significant progress in the realm of cancer treatment with its innovative immunotherapy drug, GTB-3650.…
GT Biopharma Advances Immunotherapy for Blood Cancers with GTB-3650 GT Biopharma, Inc. is making significant progress in the realm of cancer treatment through its innovative immunotherapy drug, GTB-36…
Geron Corporation Focuses on Advancing Clinical Trials Amid Industry Challenges Geron Corporation, a leader in the development of therapies for hematologic malignancies, is currently navigating a comp…
Geron Corporation Prepares for Key Earnings Report Amid Clinical Advances Geron Corporation is set to release its quarterly earnings report on November 5, 2025, a pivotal moment for the company as sta…
Geron's Clinical Advancements and Upcoming Earnings Report: A Crucial Moment for Stakeholders Geron Corporation is poised to release its quarterly earnings report on November 5, 2025, a critical event…
Geron Corporation Prepares for Key Earnings Report Amid Clinical Advancements Geron Corporation is set to release its quarterly earnings report on November 5, 2025, a highly anticipated event for stak…
Taysha Gene Therapies Poised for Significant Earnings Report Amidst Gene Therapy Advancements As Taysha Gene Therapies approaches the release of its quarterly earnings report on August 12, 2025, the b…
Taysha Gene Therapies Poised for Key Earnings Report Amidst Competitive Landscape Taysha Gene Therapies (TSHA) is preparing to unveil its quarterly earnings report on August 12, 2025, a significant ev…
Geron Corporation Enhances Clinical Development with New Research Initiatives Geron Corporation, a biotechnology company specializing in telomerase inhibition for cancer treatment, announces significa…
Geron Announces Positive Developments in Cancer Treatment Pipeline Geron Corporation continues to make strides in the field of oncology with its leading drug candidate, imetelstat. The company announc…
Geron Advances in Myelofibrosis Treatment with Promising Clinical Trial Results Geron Corporation, a clinical-stage biopharmaceutical company focused on developing therapies for hematologic malignanci…
Geron Corporation Expands Workforce to Drive Innovation in Blood Cancer Treatment Geron Corporation, a biopharmaceutical company headquartered in Foster City, California, takes a strategic step to bol…
Geron Corporation Expands Workforce with New Equity Awards Geron Corporation, a biopharmaceutical company headquartered in Foster City, California, has recently enhanced its talent pool by granting eq…
Geron Corporation's Strategic Initiative to Attract Talent through Stock Options Geron Corporation, a biopharmaceutical company focused on innovative therapies for blood cancers, recently announces a…
Geron Corporation's Commitment to Advancing Blood Cancer Treatment Geron Corporation, a biopharmaceutical company based in Foster City, California, is dedicated to revolutionizing the treatment landsc…
Geron Corporation Expands Workforce with Incentive Stock Options for New Employees Geron Corporation, a commercial-stage biopharmaceutical company dedicated to advancing treatments for blood cancer, t…
Geron Corporation Strengthens Leadership to Advance Blood Cancer Treatments Geron Corporation, a biopharmaceutical company dedicated to innovating therapies for blood cancers, announces the appointmen…
Geron Corporation Strengthens Leadership to Advance Blood Cancer Treatments Geron Corporation, a biopharmaceutical company dedicated to transforming the treatment landscape for blood cancers, announce…
Geron Corporation's Strategic Shift in Blood Cancer Treatment Geron Corporation continues to pave its path in the biopharmaceutical landscape with the successful launch of its drug RYTELO (imetelstat)…